New hope for kidney patients: drug aims to prevent relapse
NCT ID NCT07604311
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a 15-month course of Nefecon can prevent proteinuria relapse in 288 adults with IgA nephropathy who have already achieved remission. Participants must have completed prior Nefecon therapy and have stable kidney function. The goal is to see if maintenance treatment can keep the disease under control and slow progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nefecon (a targeted corticosteroid)
- What this could lead to
- If successful, this could offer a maintenance therapy to keep IgA nephropathy in remission and delay kidney disease progression.
- What could go wrong
- This is a phase 4 trial, but it is not yet recruiting. The benefit is only for patients already in remission, and long-term steroid use carries risks like infection or metabolic effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mapping the Real-World treatment landscape for IgA nephropathy
- A simple test could forecast kidney disease progression
- Can engineered immune cells tame autoimmune kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
- Experimental drug aims to protect kidneys in inflammatory diseases
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis